PubMed · 2893186
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D Brahams. 1988-02-13. 'Opren' case arbitration.. https://doi.org/10.1016/s0140-6736(88)91175-0
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A Bayesian methodology is developed to investigate the homogeneity of the treatment effects in a multi-centre clinical trial with an ordinal response. A hierarchical model is formulated for the ordinal response, and the marginal posterior distributions of the covariates, overall treatment and the centre effects are calculated using the Gibbs sampler. The methodology is applied to data arising from a multi-centre clinical trial of therapies for acute myocardial infarction. In this trial, the overall results show that the treatment is effective. However, there appears to be substantial differences in both the baseline risk and treatment effect across centres. Thus, the observed treatment effects may not be generalized to a broader patient population, and exploratory analyses to ascertain reasons for the treatment-by-centre interaction and its possible effect on the study conclusions would be useful.
A unified synthesis of several quinone sesquiterpenes is described herein. Essential to this strategy is a novel radical addition reaction that permits the attachment of a fully substituted bicyclic core 16 to a variably substituted quinone 10. The addition product 15 can be further functionalized, giving access to natural products with a high degree of oxygenation at the quinone unit. The quinone addition reaction is characterized by excellent chemoselectivity, taking place only at conjugated and unsubstituted double bonds, and regioselectivity, being strongly influenced by the resonance effect of heteroatoms located on the quinone ring. These features were successfully applied to the synthesis of avarol (1), avarone (2), methoxyavarones (4, 5), ilimaquinone (6), and smenospongidine (7), thereby demonstating the synthetic value of this new method.
DP-VPA (SPD 421) is a new compound, where valproic acid is chemically bound to lecithin. It is a novel prodrug of valproic acid with targeted action for the treatment of epilepsy. RP-HPLC stability indicating method has been developed for this and relative compounds. Versatile detection techniques could be used with these LC procedures. The absence of non-volatile components in the mobile phase allows running the method with evaporative light scattering and MS-detectors. The method appeared to be sensitive, selective, reproducible, and stability indicating. It could be easily upgraded to bioanalytical procedures applying LC-MS technique. The method could be used as 'generic' for numerous compounds having similar design of the molecules, such as lecithin-based derivatives of diclofenac, naproxen, ibuprofen, and indometacin. The strategy of HPLC method development for polar lipids is discussed.